A Customizable Platform to Integrate CAR and Conditional Expression of Immunotherapeutics in T Cells.

ABSTRACT: The potential of chimeric antigen receptor (CAR)-based immunotherapy as a promising therapeutic approach is often hindered by the presence of highly immunosuppressive tumor microenvironments (TME). Combination therapies with either co-administration or built-in expression of additional TME-modulating therapeutic molecules to potentiate the functions of CAR-T cells can cause systemic toxicities due to the lack of control over the delivery of biologics. Here, we present a proof-of-concept engineered platform in human Jurkat T cells that combines CAR with a therapeutic gene circuit capable of sensing β-galactosidase (a reported cancer-associated signal) and subsequently activate the production of customized therapeutic gene products. We have demonstrated the integration of the chemical

SUBMITTER: Nguyen HTX 

PROVIDER: S-EPMC11476998 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature